Percutaneous endoscopic gastrostomy (PEG) is a wellestablished and commonly practised method to provide a route for enteral feeding. It is a relatively low-risk procedure, is well tolerated 1 and, compared with surgical gastrostomy, is the preferred method of insertion of gastrostomy tube due to a reduced complication rate.
Safety surrounding endoscopic procedures, particularly PEG insertion, is an important issue and the role of preassessment to establish the suitability for PEG insertion was advocated by the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) report Scoping our practice. 5 The 2005 Feed Or Ordinary Diet (FOOD) trial demonstrated increased mortality following early PEG placement (within one week) following cerebrovascular accident, compared with nasogastric (NG) feeding, emphasising the difficulties in the timing of PEG placement. 6 Many patients who require PEG feeding are frail, have multiple co-morbid conditions and are therefore at risk from both sedation and endoscopic intervention. Patient selection is important and a multidisciplinary assessment framework has been shown to reduce early post-PEG mortality in our unit. 7 In the period 2003-04, when preassessment was introduced, we recorded a zero oneweek mortality. 7 However, in subsequent years following this study, despite continued pre-assessment, there has been an increase in one-week post-PEG mortality and we considered early post-PEG aspiration as a cause. We also questioned whether the use of sedation was contributing to aspiration in our patients. Intravenous midazolam is the benzodiazepine of choice for sedation in most endoscopy units. Flumazenil (Annexate ® , Roche) is a benzodiazepine receptor antagonist which is approved for the reversal of sedation from benzodiazepines used during therapeutic procedures. 8 Importantly, the pharmacokinetics of midazolam are such that it has a longer duration of action than a single bolus of flumazenil, particularly in older patients. 9 As a result of concerns about the increase in one-week post-PEG mortality, possibly as a result of prolonged sedation in elderly patients, we instigated a change in practice: the routine use of flumazenil as a continuous
The routine use of a flumazenil infusion following percutaneous endoscopic gastrostomy placement to reduce early post-procedure mortality infusion following a single bolus, to eliminate the effects of midazolam in the post-PEG insertion period. We also postulated that aspiration rates may be increased with the use of local anaesthetic throat spray, therefore we wished to investigate the effect of using midazolam alone, compared with the addition of local anaesthetic throat spray.
PAtIentS/mAterIAlS And methodS
This paper is a retrospective audit of prospectively collected data for patients accepted for PEG placement in a UK district general hospital. Data were collected for individual years (August to July) and protocols were altered at the beginning of each year. After receiving PEG referral, multidisciplinary pre-assessment was carried out to establish patient suitability to undergo PEG insertion. In an effort to reduce procedure-related confounders, more than 95% of PEG tubes were placed by a single consultant gastroenterologist or specialist registrar under his supervision, assisted by a single clinical nurse specialist. All patients received intra-nasal oxygen therapy and continuous oxygen saturation monitoring during the procedure and recovery. The patient demographics are shown in Table 1 .
Patients were given pre-procedure antibiotics as recommended by the British Society of Gastroenterology (BSG). 10 Freka ® (Fresenius Kabi) 15-Fr gauge tubes were inserted endoscopically. Specific changes in procedure protocol are outlined in Table 2 .
Data for all patients were entered into a database (Microsoft Access) and information regarding mortality at one week and one month as well as clinically apparent aspiration episodes was recorded prospectively by review of patient notes or by telephone.
The regimen used for reversal of sedation was designed so as to ensure antagonism until full benzodiazepine clearance. 11 An initial bolus of 500 mg flumazenil was followed by 1,000 mg made up to a volume of 50 ml, infused over 10 hours intravenously.
Patients under general anaesthetic and those on longterm benzodiazepine therapy were excluded from the study as neither group received flumazenil. We also excluded patients under the age of 50 years as these patients did not receive flumazenil infusion because the risk of benzodiazepine toxicity is low. In the study period 2005 to 2008, 79% of patients undergoing PEG insertion in our unit received the flumazenil regimen. Statistical analysis was performed using Stata Version 10 (StataCorp).
reSultS Table 1 shows the demographics of the study population, Table 2 outlines the protocol changes and the doses of sedation administered and Figure 1 In 2004, lidocaine throat spray was used in conjunction with a titrated dose of midazolam to improve toleration of the procedure and allow as small a dose of sedation as possible to be administered. The changes in protocol outlined in Table 2 show that, when routine reversal of sedation was commenced, the use of lidocaine spray was withdrawn. The dose of midazolam used was still determined by dose titration and procedure tolerance. We show a trend towards using more midazolam (a mean dose of 3. 
Complication summary
In the study period from 2005 to 2008, six procedures failed on account of inability to intubate the oesophagus or anatomical problems preventing safe PEG insertion. There were no identifiable adverse events related to the use of flumazenil; particularly, there were no seizures.
dIScuSSIon
The pharmacokinetics of midazolam are altered with age, with evidence that the half-life is prolonged in older patients. 8 A study that analysed patients undergoing minor surgery found the elimination half-life of midazolam to be 2.4 hours for patients aged less than 50 and 4.1 hours for those aged over 50, explained by alterations in clearance and volume of distribution of the drug with advancing age. 11 Drug elimination is likely to be further reduced by the effect of the comorbidities encountered in patients who undergo PEG insertion, for example cardiac failure. clinical One characteristic of flumazenil's pharmacodynamic profile is a dose-dependent effect with regard to benzodiazepine antagonism. The duration and degree of benzodiazepine reversal is related to the plasma concentrations of both the benzodiazepine involved and flumazenil. Benzodiazepines and their metabolites also undergo a high degree of protein-binding. In disease states, the fraction of unbound drug can be increased, resulting in a toxic condition despite normal serum benzodiazepine levels. 9 In order to ensure complete reversal of the benzodiazepine, multiple dosing or a prolonged infusion of flumazenil is required, particularly in older or dehydrated patients, with prolonged benzodiazepine pharmacokinetics. Continuous infusions of flumazenil, used in benzodiazepine overdose, are safe where bolus injection is insufficient to counter the resedating effect of the benzodiazepine. 9 We have confirmed that the routine use of flumazenil following benzodiazepine sedation specifically following PEG insertion is safe. This assumes that there is no identified contraindication, such as patients with epilepsy who are taking long-term benzodiazepines or antidepressants, for whom the use of flumazenil may lower seizure threshold. Our aspiration rates in the first week after PEG insertion are similar in the pre-and post-flumazenil datasets and higher than in the published literature, 4 possibly due to the diagnostic threshold used to define an aspiration episode. Our results show a trend towards a rising midazolam dose corresponding to the withdrawal of lidocaine throat spray and postulate that the use of local anaesthetic may allow a lower titrated dose of benzodiazepine to be used.
Our population demographics were comparable year on year, with around 50% of patients being referred for PEG insertion on account of stroke disease. We have shown an overall reduction in post-PEG mortality since 2003, which is likely to be primarily the effect of robust patient selection through pre-assessment, co-ordinated by a dedicated PEG nurse.
This study supports previous data that showed flumazenil infusions to be safe and well tolerated. 9 Although there is a trend to suggest that the routine use of a flumazenil infusion may reduce post-PEG mortality and aspiration, this is not statistically significant and other changes in practice were implemented during the study period. Furthermore, although there may have been a small effect on one-week post-procedure mortality, the onemonth post procedure mortality rate remained at 21-24% in the years after routine flumazenil infusion was introduced. This emphasises how severely unwell are patients who require a PEG, particularly older patients with co-morbidity recovering from a stroke.
Although interesting, our results do not clearly demonstrate that the routine use of sedation reversal following PEG insertion confers improvement in mortality, and thus prospective randomised studies would be required to further investigate the potential advantage of this intervention, which may be particularly beneficial for patients who are at the highest risk of aspiration. However, until such studies are performed, the routine use of a flumazenil infusion cannot be justified.
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